Advisors Asset Management Inc. Makes New Investment in Gilead Sciences, Inc. $GILD

Gilead Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management initiated a position in Gilead Sciences, buying 237,816 shares worth approximately $35.4 million in the third quarter. Institutional investors collectively own 83.67% of the company.
  • Gilead reported quarterly revenue of $8.30 billion and EPS of $2.55, beating analyst estimates; revenue rose 6.8% year over year.
  • Analysts give Gilead a consensus “Moderate Buy” rating, with an average price target of $171.63. The company also declared a quarterly dividend of $0.82 per share.
  • Interested in Gilead Sciences? Here are five stocks we like better.

Advisors Asset Management Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 237,816 shares of the biopharmaceutical company's stock, valued at approximately $35,446,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new position in Gilead Sciences in the second quarter valued at $25,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences during the second quarter worth about $25,000. PFS Partners LLC boosted its holdings in shares of Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $29,000. Finally, Wiser Advisor Group LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $30,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.4%

Shares of Gilead Sciences stock opened at $166.53 on Friday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The company's 50 day moving average price is $156.80 and its 200-day moving average price is $142.34. The stock has a market capitalization of $206.55 billion, a price-to-earnings ratio of -52.70 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion during the quarter, compared to analysts' expectations of $7.81 billion. During the same quarter in the prior year, the company posted $2.47 EPS. The firm's revenue for the quarter was up 6.8% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences's dividend payout ratio is presently -103.80%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $171.47, for a total transaction of $514,410.00. Following the transaction, the chief financial officer directly owned 158,096 shares of the company's stock, valued at approximately $27,108,721.12. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total value of $4,775,400.00. Following the transaction, the insider owned 110,684 shares of the company's stock, valued at approximately $18,877,156.20. This represents a 20.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 237,709 shares of company stock worth $39,799,137. Corporate insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Scotiabank increased their price objective on Gilead Sciences from $177.00 to $200.00 and gave the company a "sector outperform" rating in a research report on Friday, October 30th. Sanford C. Bernstein restated an "outperform" rating and issued a $175.00 target price on shares of Gilead Sciences in a research report on Monday, November 2nd. Royal Bank Of Canada boosted their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a "sector perform" rating in a research report on Friday, October 30th. Barclays upped their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock an "equal weight" rating in a research note on Monday. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $171.63.

Get Our Latest Report on GILD

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines